These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 2789392

  • 1. Adoptive cellular therapy of renal carcinoma.
    West WH.
    Prog Clin Biol Res; 1989; 303():689-96. PubMed ID: 2789392
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
    Aso Y, Tazaki H, Umeda T, Marumo K.
    Prog Clin Biol Res; 1989; 303():681-8. PubMed ID: 2675018
    [No Abstract] [Full Text] [Related]

  • 3. Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.
    Javadpour N, Lalehzarian M.
    Prog Clin Biol Res; 1989; 303():671-9. PubMed ID: 2789391
    [No Abstract] [Full Text] [Related]

  • 4. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 5. Advances in management of disseminated renal cell carcinoma.
    Javadpour N.
    Prog Clin Biol Res; 1988 Dec; 277():85-91. PubMed ID: 3263656
    [No Abstract] [Full Text] [Related]

  • 6. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA, Pierce WC, Belldegrun A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Bacteremia caused by Streptococcus equisimilis in a neoplastic patient treated with recombinant interleukin 2].
    Pedro-Botet ML, Ribelles Entrena N, Carrasco Miserachs I, Carles Galcerán J, Sabria-Leal M, Arnal J.
    Enferm Infecc Microbiol Clin; 1990 Dec; 8(10):659-60. PubMed ID: 2098130
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant interleukin-2 and the quest for FDA approval.
    Tami JA.
    Clin Pharm; 1991 Feb; 10(2):141-2. PubMed ID: 2009733
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [Abstract] [Full Text] [Related]

  • 14. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC, Belldegrun A, Figlin RA.
    Semin Oncol; 1995 Feb 01; 22(1):74-80. PubMed ID: 7855622
    [No Abstract] [Full Text] [Related]

  • 15. Interleukin-2.
    Med Lett Drugs Ther; 1987 Sep 25; 29(749):88-9. PubMed ID: 3306301
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
    Litwin MS, Fine JT, Dorey F, Figlin RA, Belldegrun AS.
    J Urol; 1997 May 25; 157(5):1608-12. PubMed ID: 9112487
    [Abstract] [Full Text] [Related]

  • 19. Renal cell carcinoma: current status and future plans.
    Figlin RA.
    Cancer J Sci Am; 2000 Feb 25; 6 Suppl 1():S52-4. PubMed ID: 10685659
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.